THCV Cannabinoid Composition for Weight Loss With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity, such as Rimonabant, Sibutramine, and Orlistat, have modest weight reduction effects and significant side effects, and there is a need for natural, non-synthetic alternatives.
Innovation Solution
A pharmaceutical composition comprising tetrahydrocannabivarin (THCV) with cannabigerol (CBG) or cannabinodiol (CBND) or their mixtures, administered in specific ratios, to induce weight loss and suppress appetite.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current obesity treatments (Rimonabant, Sibutramine, Orlistat) are used, then weight reduction is achieved, but side effects increase and weight loss magnitude is limited
Solution Approach 1:
The patent combines multiple cannabinoids (THCV as the primary active ingredient with CBG and/or CBD as additional components) to create a composite pharmaceutical composition. This composite approach leverages the synergistic effects of different cannabinoids to achieve weight reduction while potentially reducing side effects compared to single-compound treatments like Rimonabant, Sibutramine, or Orlistat.
Solution Approach 2:
The patent specifies precise parameter ranges for the cannabinoid composition, including THCV content (0.1-50% w/w), CBG content (0.1-20% w/w), and CBD content (0.1-20% w/w), along with controlled levels of other cannabinoids. By optimizing these compositional parameters, the invention aims to achieve effective weight reduction while minimizing harmful side effects.
2Quantity of substance
If current obesity treatments are used, then some weight loss is achieved, but the weight loss magnitude is insufficient for severely obese patients
Solution Approach 1:
The multi-component cannabinoid composition is designed to provide more reliable and potentially greater weight reduction efficacy compared to single-drug treatments. The synergistic interaction between THCV, CBG, and CBD may produce enhanced metabolic effects that are more effective for severely obese patients who have not responded adequately to conventional monotherapies.
Solution Approach 2:
The cannabinoid composition targets multiple physiological pathways simultaneously, including appetite suppression, metabolic rate enhancement, and fat metabolism regulation. This multi-functional approach increases the reliability of treatment across diverse patient populations with varying degrees of obesity and different underlying metabolic profiles.
3Quantity of substance
If synthetic obesity medications are used, then weight reduction is achieved, but natural alternatives are needed to reduce side effects
Solution Approach 1:
The patent utilizes naturally occurring cannabinoids from the Cannabis plant as alternative therapeutic agents. These natural compounds serve as short-living, biodegradable molecules that the body can metabolize and eliminate more readily than synthetic pharmaceuticals, potentially reducing the accumulation of harmful metabolites and long-term side effects.
Solution Approach 2:
The invention repurposes cannabinoids, which have historically been associated with recreational use and potential abuse, into a therapeutic weight management solution. By carefully controlling the composition and dosage, the harmful aspects are minimized while the beneficial metabolic and appetite-regulating effects are harnessed for treating obesity.
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising a tetrahydrocannabivarin (THCV), wherein the composition further comprises cannabigerol (CBG) or cannabinodiol (CBND) or a mixture thereof, for use in the prevention and treatment of overweight, preferably associated with obesitas. The pharmaceutical composition according to the invention may further comprise the following additional compounds tetrahydrocannabinol (THC), or Cannabigerol (CBG) or Cannabinodiol (CBND) or a combination thereof.